TAK-448 (CAS 1234319-68-6) – GMP Manufacturer

$2.00

TAK-448, also known as MVT-602, is a potent KISS1R agonist peptide that stimulates LH/FSH release and shows anti-tumor activity in models. Purity ?99.90%, GMP quality, available in wholesale/retail formats. For laboratory research use only.?For wholesale prices, other specifications and uses, please consult our staff?

Compare

Description

TAK-448 (MVT-602) is a synthetic nonapeptide agonist of the kisspeptin receptor (KISS1R, also GPR54). It showcases exceptional potency (IC?? ~460 pM; EC?? ~632 pM), stimulating luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release in acute dosing, and suppressing the pituitary–gonadal axis upon continuous administration. In preclinical models, TAK-448 exhibited strong antitumor effects in androgen-dependent prostate cancer. Manufactured in a GMP-compliant facility with ?99.90% purity, this peptide is ideal for endocrinology and oncology research. For laboratory research use only.

Contents hide

1 Product Specifications

2 Mechanism of Action & Research Applications

3 Side Effects (For Reference Only in Models)

4 Disclaimer

Product Specifications

Parameter	Details
Product Name	TAK-448 (MVT-602)
Synonyms	MVT-602; RVT-602
CAS No.	1234319-68-6
Purity	?99.90% (GMP-grade)
Target Receptor	KISS1R (kisspeptin receptor)
Potency	IC?? ? 460 pM; EC?? ? 632 pM
Appearance	Solid peptide powder
Solubility	Soluble in DMSO; aqueous solubility requires optimization
Storage Conditions	Store lyophilized at -20 °C, protect from moisture and light
Manufacturing Standard	GMP-compliant production
Applications	Reproductive hormone regulation, oncology models, neuroendocrine research
Regulatory Status	For laboratory research use only

Mechanism of Action & Research Applications

TAK-448 functions as a highly selective, full agonist of the kisspeptin receptor (KISS1R), triggering gonadotropin release (LH and FSH) with remarkable potency. Acute administration elevates reproductive hormone levels; chronic dosing suppresses the pituitary–gonadal axis and testosterone production. In prostate cancer models (VCaP xenografts), TAK-448 demonstrated compelling antitumor efficacy. These properties make it suitable for endocrine, reproductive, and oncology research. For laboratory research use only.

Side Effects (For Reference Only in Models)

In preclinical rodent models, continuous TAK-448 dosing led to suppressed testosterone levels and pituitary–gonadal axis down-regulation. Other effects may include transient endocrine alterations or stress axis modulation. These observations are model-specific and intended for research context only. For laboratory research use only.

Disclaimer

This product is intended strictly for laboratory research use only. It is not approved for human, veterinary, or clinical use. All handling must follow institutional safety protocols.